Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Repligen Corp’s stock clocked out at $149.06, up 3.11% from its previous closing price of $144.57. In other words, the price has increased by $3.11 from its previous closing price. On the day, 1.18 million shares were traded. RGEN stock price reached its highest trading level at $153.415 during the session, while it also had its lowest trading level at $144.21.
Ratios:
To gain a deeper understanding of RGEN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 79.15. For the most recent quarter (mrq), Quick Ratio is recorded 7.32 and its Current Ratio is at 8.59. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, HSBC Securities on October 01, 2025, initiated with a Buy rating and assigned the stock a target price of $150.
On September 22, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $155.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 10 ’25 when Hunt Anthony sold 29,111 shares for $120.52 per share. The transaction valued at 3,508,389 led to the insider holds 100,743 shares of the business.
Hunt Anthony bought 29,111 shares of RGEN for $3,508,378 on Sep 10 ’25. On Aug 08 ’25, another insider, Madaus Martin D, who serves as the Director of the company, bought 1,800 shares for $112.13 each. As a result, the insider paid 201,830 and bolstered with 1,800 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 8385760256 and an Enterprise Value of 8362969600. As of this moment, Repligen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6775.45, and their Forward P/E ratio for the next fiscal year is 71.07. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 340.30. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.85 while its Price-to-Book (P/B) ratio in mrq is 4.07. Its current Enterprise Value per Revenue stands at 11.814 whereas that against EBITDA is 55.707.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.15, which has changed by 0.068300724 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is 10.04%, while the 200-Day Moving Average is calculated to be 10.39%.
Shares Statistics:
It appears that RGEN traded 912.01K shares on average per day over the past three months and 1286740 shares per day over the past ten days. A total of 56.26M shares are outstanding, with a floating share count of 53.15M. Insiders hold about 5.52% of the company’s shares, while institutions hold 98.43% stake in the company. Shares short for RGEN as of 1760486400 were 3382265 with a Short Ratio of 3.71, compared to 1757894400 on 3541604. Therefore, it implies a Short% of Shares Outstanding of 3382265 and a Short% of Float of 8.1099994.
Earnings Estimates
. The current market rating for Repligen Corp (RGEN) reflects the collective analysis of 18.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.45, with high estimates of $0.51 and low estimates of $0.31.
Analysts are recommending an EPS of between $1.7 and $1.65 for the fiscal current year, implying an average EPS of $1.67. EPS for the following year is $2.1, with 19.0 analysts recommending between $2.47 and $1.76.
Revenue Estimates
In . The current quarter, 17 analysts expect revenue to total $192.79M. It ranges from a high estimate of $194.25M to a low estimate of $189M. As of . The current estimate, Repligen Corp’s year-ago sales were $167.55MFor the next quarter, 17 analysts are estimating revenue of $191.51M. There is a high estimate of $195.82M for the next quarter, whereas the lowest estimate is $186.8M.
A total of 19 analysts have provided revenue estimates for RGEN’s current fiscal year. The highest revenue estimate was $734.6M, while the lowest revenue estimate was $729.3M, resulting in an average revenue estimate of $732.98M. In the same quarter a year ago, actual revenue was $634.44MBased on 19 analysts’ estimates, the company’s revenue will be $825.24M in the next fiscal year. The high estimate is $847.15M and the low estimate is $794.14M.
